AbbVie and Genmab Receive EC’s Conditional Marketing for Tepkinly (epcoritamab) to Treat Relapsed or Refractory Diffuse Large B-ce...
September 26, 2023
AbbVie Terminates the Development and Option Agreement with Harpoon Therapeutics for HPN217
September 14, 2023
AbbVie’s Skyrizi (risankizumab) Meet Primary and Secondary Endpoints in P-III (SEQUENCE) Head-to-Head Study for Crohn's Disease
September 13, 2023
AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults
September 4, 2023
AbbVie’s Aquipta (atogepant) Receives EC’s Approval for the Preventive Treatment of Migraine in Adults
August 17, 2023
AbbVie Reports P-IV (IMMpulse) Study Results of Skyrizi (risankizumab) for Adult Patients with Moderate Plaque Psoriasis
July 27, 2023
Back to Home
Incisive News in 3 Shots.
First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2023 PharmaShots - All Rights Reserved.